Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol and rifaximin for portal hypertension in cirrhosis
ACTRN12612001026819Phase 2Not yet recruiting
- Sponsor
- Professor Stephen Riordan
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of propranolol and rifaximin in Portal Hypertension (PH) and Cirrhosis (3 arms), sponsored by Professor Stephen Riordan. Primary endpoint: Portal venous pressure. Planned start Oct 2012; status: not yet recruiting.
02
Drugs
propranololrifaximin
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on ACTRN12612001026819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001026819.